| 2025 | 2024 | 2023 | |||
|---|---|---|---|---|---|
| Financial Performance (Baht ‘000) | |||||
| Total current assets | 18,781,379 | 16,731,530 | 15,684,977 | ||
| Total assets | 36,458,525 | 32,653,045 | 29,212,105 | ||
| Trade receivables | 4,249,871 | 3,820,961 | 4,264,339 | ||
| Inventories | 371,167 | 355,939 | 362,256 | ||
| Total current liabilities | 4,085,395 | 3,826,729 | 4,184,351 | ||
| Total liabilities | 5,287,588 | 4,852,114 | 5,114,316 | ||
| Trade payables | 905,715 | 1,060,738 | 995,238 | ||
| Total shareholders’ equity | 31,170,937 | 27,800,931 | 24,097,789 | ||
| Total revenues | 25,448,911 | 25,862,450 | 25,574,976 | ||
| Total expenses | 16,367,073 | 16,697,114 | 17,074,978 | ||
| Share of income(loss) from investments in joint venture and associated companies | (882) | (427) | (897) | ||
| Profit before finance cost and income tax expenses | 9,307,632 | 9,444,382 | 8,640,049 | ||
| Net profit excluding extraordinary Items | 7,501,301 | 7,774,726 | 7,006,451 | ||
| Net profit for the year | 7,511,763 | 7,774,726 | 7,006,451 | ||
| Basic earnings per share | 9.45 | 9.78 | 8.81 | ||
| Earnings per share - fully diluted | 8.66 | 8.96 | 8.08 | ||
| Book value per share | 39.21 | 34.97 | 30.32 | ||
| Book value per share - fully diluted | 35.94 | 32.05 | 27.78 | ||
| Dividend per share | 11.00 | 5.00 | 4.50 | ||
| Net cash flows from operating activities | 8,253,244 | 8,671,234 | 7,094,365 | ||
| Net cash flows used in investing activities | 197,931 | (4,984,873) | (2,428,594) | ||
| Net cash flows used in financing activities | (4,099,625) | (4,224,199) | (3,050,793) | ||
| Financial Ratios | |||||
| Gross profit margin (%) | 54.3 | 53.8 | 51.6 | ||
| EBIT Margin (%) | 35.7 | 35.4 | 33.2 | ||
| EBITDA margin (%) | 39.9 | 39.6 | 37.5 | ||
| Net profit margin excluding extraordinary items (%) | 29.5 | 30.1 | 27.4 | ||
| Net profit margin (%) | 29.5 | 30.1 | 27.4 | ||
| Growth on revenues from hospital operations (%) | -2.0 | 1.3 | 22.5 | ||
| Growth on net profit excluding extraordinary Items (%) | -1.7 | 11.0 | 41.9 | ||
| Growth on net profit for the year (%) | -3.4 | 11.0 | 41.9 | ||
| Return on equity excluding extraordinary Items (%) | 25.4 | 30.0 | 31.8 | ||
| Return on equity (%) | 25.5 | 30.0 | 31.8 | ||
| Return on assets excluding extraordinary Items (%) | 21.7 | 25.1 | 26.2 | ||
| Return on assets (%) | 21.7 | 25.1 | 26.2 | ||
| Liabilities to equity (x) | 0.2 | 0.2 | 0.2 | ||
| Debt to equity (x) | 0.0 | 0.0 | 0.0 | ||
| Net debt to equity (x) | (0.2) | (0.1) | (0.2) | ||
| Interest coverage ratio (x) | 1,531.3 | 1,228.9 | 4,008.7 | ||
| IBD/EBITDA (x) | 0.0 | 0.0 | 0.0 | ||
| DSCR (x) | 944 | 955 | 892 | ||
| IBD1Year/IBD (%) | 32.2 | 30.6 | 30.8 | ||
| Liquidity ratio (x) | 4.6 | 4.4 | 3.7 | ||
| Cash Cycle (days) | 44.4 | 42.2 | 36.1 | ||
| Average collection Period (days) | 60.5 | 59.8 | 52.4 | ||
| Average inventory Period (days) | 11.4 | 10.9 | 10.1 | ||
| Average payable Period (days) | 27.5 | 28.5 | 26.4 | ||
Remarks: IBD means interest-bearing debt, which excludes liabilities under finance lease agreements.
